Natural products in anticancer therapy
Tóm tắt
Từ khóa
Tài liệu tham khảo
Farnsworth, 1985, Medicinal plants in therapy, Bull World Health Organ, 63, 965
Cragg, 1997, Natural products in drug discovery and development, J Nat Prod, 60, 52, 10.1021/np9604893
Balandrin, 1993, Plant-derived natural products in drug discovery and development: an overview, 2
Farnsworth, 1990, The role of ethnopharmacology in drug development, Ciba Found Symp, 154, 2
Cragg, 1999, Discovery and development of antineoplastic agents from natural sources, Cancer Invest, 17, 153, 10.3109/07357909909011730
Wani, 1971, Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia, J Am Chem Soc, 93, 2325, 10.1021/ja00738a045
Schwartsmann, 2000, Marine organisms and other novel natural sources of new anticancer drugs, Ann Oncol, 11, 235, 10.1023/A:1011160906608
Schwartsmann, 2001, Marine organisms as a source of new anticancer agents, Lancet Oncol, 2, 221, 10.1016/S1470-2045(00)00292-8
Mans, 2000, Anti-cancer drug discovery and development in Brazil: targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds, Oncologist, 5, 185, 10.1634/theoncologist.5-3-185
Noble, 1990, The discovery of the vinca alkaloids – chemotherapeutic agents against cancer, Biochem Cell Biol, 68, 1344, 10.1139/o90-197
DeVita, 1970, Combination chemotherapy in the treatment of advanced Hodgkin's disease, Ann Intern Med, 73, 881, 10.7326/0003-4819-73-6-881
Williams, 1987, Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide, New Engl J Med, 316, 1435, 10.1056/NEJM198706043162302
Stähelin, 1973, Actvity of a new glycosidic lignan derivative (VP-16-213) related to podophyllotoxin in experimental tumors, Eur J Cancer, 9, 215, 10.1016/S0014-2964(73)80021-0
Chabner, 1991, Anticancer drugs, 325
Perry, 1992
Harvey, 1999, Medicines from nature: are natural products still relevant to drug discovery?, Trends Pharmacol Sci, 20, 196, 10.1016/S0165-6147(99)01346-2
Liu, 1989, DNA topoisomerase poisons as antitumor drugs, Annu Rev Biochem, 58, 351, 10.1146/annurev.bi.58.070189.002031
Creemers, 1996, Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer, J Clin Oncol, 14, 3056, 10.1200/JCO.1996.14.12.3056
Bertino, 1997, Irinotecan for colorectal cancer, Semin Oncol, 24, S18
Liu, 2000, Mechanism of action of camptothecin, Ann New York Acad Sci, 922, 1, 10.1111/j.1749-6632.2000.tb07020.x
Kelland, 2000, Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status, Expert Opin Invest Drugs, 9, 2903, 10.1517/13543784.9.12.2903
Harmon, 1979, The structure of rohutukine, the main alkaloid of Amoora rohituka (syn. Aphanamixis polystachya) (Maliaceae), Tetrahydron, 20, 721, 10.1016/S0040-4039(01)93556-7
Cragg, 1988, Metabolism of plant-derived anticancer agents, Pharmacol Ther, 37, 425, 10.1016/0163-7258(88)90006-X
Worland, 1993, Alteration of the phosphorylation state of p32cdc2 kinase by the flavone L86-8275 in breast carcinoma cells, Biochem Pharmacol, 46, 1831, 10.1016/0006-2952(93)90590-S
Losiewicz, 1994, Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275, Biochem Biophys Res Commun, 201, 589, 10.1006/bbrc.1994.1742
Senderowicz, 1998, Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms, J Clin Oncol, 16, 2986, 10.1200/JCO.1998.16.9.2986
Wright, 1998, Clinical trials referral resource. Clinical trials of flavopiridol, Oncology, 12, 1023
Kaur, 1992, Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275, J Natl Cancer Inst, 84, 1736, 10.1093/jnci/84.22.1736
Powell, 1970, Structures of harringtonine, isoharringtonine, and homoharringtonine, Tetrahydron Lett, 11, 815, 10.1016/S0040-4039(01)97839-6
Kantarjian, 1996, Treatment of myelogenous leukemia: current status and investigational options, Blood, 87, 3069, 10.1182/blood.V87.8.3069.bloodjournal8783069
Zhou, 1995, Homoharringtonine: an effective new natural product in cancer chemotherapy, Bull Cancer, 82, 987
Rehm, 1993, Acute effects of 4-ipomeanol on experimental lung tumors with bronchiolar or alveolar cell features in Syrian hamsters or C3H/HeNCr mice, J Cancer Res Clin Oncol, 120, 41, 10.1007/BF01200723
Rowinsky, 1993, Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans, Cancer Res, 53, 1794
Li, 1999, Release of mitochondrial cytochrome c in both apoptosis and necrosis induced by β-lapachone in human carcinoma cells, Mol Med, 4, 232, 10.1007/BF03402120
Cragg, 1997, Coral reefs, forests, and thermal vents: the worldwide exploration of nature for novel antitumor agents, Semin Oncol, 24, 156
Binaschi, 2000, In vivo site specificity and human isoenzyme selectivity of two topoisomerase II poisoning anthracyclines, Cancer Res, 60, 3770
Patrick, 1997, Major microbial diversity initiative recommended, AmSoc Microbiol News, 63, 417
Alberts, 1993, FKBP-Rapamycin inhibits a cyclin-dependent kinase activity and a cyclin D1-Cdk association in early Gl of an osteosarcoma cell line, J Biol Chem, 268, 22825, 10.1016/S0021-9258(18)41602-X
Schulte, 1998, The benzoquinone ansamycin 17-allylamino-17demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin, Cancer Chemother Pharmacol, 42, 273, 10.1007/s002800050817
Cadenas, 1998, Signal-transduction cascades as targets for therapeutic intervention by natural products, Trends Biotechnol, 16, 427, 10.1016/S0167-7799(98)01239-6
Adjei, 2000, Signal transduction pathway targets for anticancer drug discovery, Curr Pharmaceut Design, 6, 361, 10.2174/1381612003400821
Pomponi, 1999, The bioprocess-technological potential of the sea, J Biotechnol, 70, 5, 10.1016/S0168-1656(99)00053-X
Schweitzer, 1991, Summary of the workshop on drug development, biological diversity, and workshop on drug development, biological diversity, and economic growth, J Natl Cancer Inst, 83, 1294, 10.1093/jnci/83.18.1294
Rinehart, 2000, Antitumor compounds from tunicates, Med Res Rev, 20, 1, 10.1002/(SICI)1098-1128(200001)20:1<1::AID-MED1>3.0.CO;2-A
Chun, 1986, The first marine compound entering clinical trials as an antineoplastic agent, Invest New Drugs, 4, 279, 10.1007/BF00179597
Shin, 1991, Phase I/II clinical trial of didemnin B in non-small cell lung cancer: neuromuscular toxicity is dose-limiting, Cancer Chemother Pharmacol, 29, 145, 10.1007/BF00687325
Urdiales, 1996, Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates, Cancer Lett, 102, 31, 10.1016/0304-3835(96)04151-1
Geldof, 1999, Cytotoxicity and neurocytoxicity of new marine anticancer agents evaluated using in vitro assays, Cancer Chemother Pharmacol, 44, 312, 10.1007/s002800050983
Demetri, 2000, Ecteinascidin-743 (ET-743) induces objective responses and disease control in patients with advanced non-osseous sarcomas: results from phase II trials, Ann Oncol, 11, 126
Le Cesne, 2000, Phase II study of ET-743 in advanced soft-tissue sarcoma (ASTS) in adult: A STBSG-EORTC trial, Ann Oncol, 11, 126
Erba, 2001, Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action, Eur J Cancer, 37, 97, 10.1016/S0959-8049(00)00357-9
Damia, 2001, Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways, Int J Cancer, 92, 583, 10.1002/ijc.1221
Minuzzo, 2000, Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743, Proc Natl Acad Sci USA, 97, 6780, 10.1073/pnas.97.12.6780
Poncet, 1999, The dolastatins, a family of promising antineoplastic agents, Curr Pharm Des, 5, 139, 10.2174/1381612805666230109214008
Bai, 1990, Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain, Biochem Pharmacol, 39, 1941, 10.1016/0006-2952(90)90613-P
Pathak, 1998, Dolastatin 10 induces polyploidy, telomeric associations and apoptosis in a murine melanoma cell line, Oncol Res, 5, 373
Wright, 1999, Clinical trials referral resource. Clinical trials of dolastatin 10, Oncology, 13, 68
Pitot, 1999, Phase I trial of dolastatin 10 (NSC 376128) in patients with advanced solid tumors, Clin Cancer Res, 5, 525
Madden, 2000, Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors, Clin Cancer Res, 6, 1293
Krug, 2000, Phase II study of dolastatin 10 in patients with advanced non-small-cell lung cancer, Ann Oncol, 11, 227, 10.1023/A:1008349209956
Pagliaro, 2000, Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma, Cancer, 89, 615, 10.1002/1097-0142(20000801)89:3<615::AID-CNCR17>3.0.CO;2-J
Zonder, 2001, A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer, Clin Cancer Res, 7, 38
Propper, 1998, A phase II study of bryostatin 1 in metastatic malignant melanoma, Br J Cancer, 78, 1337, 10.1038/bjc.1998.680
Varterasian, 2000, Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia, Clin Cancer Res, 6, 825
Ahmad, 2000, Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenoside: case report, Clin Cancer Res, 6, 1328